Lipid a in cancer therapies preclinical results

Advances in Experimental Medicine and Biology

Volumn 667, Issue , 2009, Pages 101-110

  Jeannin, Jean François ^a   Reisser, Daniele ^b  

^a PSL RESEARCH UNIVERSITY   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DICLOFENAC; DT 5461; GELATINASE A; GL 60; GLA 27; INDOMETACIN; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID A; LIPID A DERIVATIVE; OM 174; SDZ MRL 953; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER THERAPY; CARCINOMATOUS PERITONITIS; COLON CANCER; CYTOKINE PRODUCTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; LIVER CARCINOMA; LIVER CELL CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR BLOOD FLOW;

ANIMALIA;

EID: 77952478057     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1603-7_9     Document Type: Article

References (65)

1. Imoro M, Yoshimura H, Sakaguchi N et al. Total synthesis of Escherichia coli lipid A. Tetrahedron Lett 1985; 26:1545-1548.
2. Gratia A, Linz R. Le phenomene de Shwartzm an dans le sarcome du cobaye. C R Soc Biol 1931; 108:427-428.
3. Shear MJ, Turner FC. Chemical treatment of tumors: isolation of hemorrhagic-producing fraction from Serratia marcescens (Bacillus prod igiosus) culture filrrate. J Natl Cancer Inst 1943; 4:81-97.
4. Strausser HR, Bober LA. Inhibition of tumor growth and survival of aged mice inoculated with Moloney tumor transplants and treated with endotoxin. Cancer Res 1972; 32:2156-2159.
5. Parr I, Wheeler E, Alexander P. Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. BrJ Cancer 1973; 27:370-389.
6. Lagadec P, Jeannin JF, Reisser D et al. Treatment with endotoxins of peritoneal carcinomatosis induced by colon tumor cells in the rat. Invasion Metastasis 1987; 7:83-95. (Pubitemid 17082858)
7. SinkovicsJG, Ahearn MJ, Shirato E et al. Viral leukemogenesis in immunologically and hematologically altered mice. J Rericuloendothel Soc 1970; 8:474-492.
8. Berendt MJ, North RJ, Kirstein DP. The immunological basis of endotoxin-induced tumor regression. Requirement for Tvccll-mcdiared immunity. J Exp Med 1978; 148:1550-1559. (Pubitemid 9084030)
9. Carswell EA, Old LJ, Kassel RL et al. An endotoxin -induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975; 72:3666-3670.
10. Mannel DN, Rosensrreich DL, Mergenhagen SE. Mechanism of lipopolysaccharide-induced tumor necrosis: requirement for lipopolysaccharide- sensitive lymphoreticular cells. Infect Immun 1979; 24:573-576. (Pubitemid 9171442)
11. Inagawa H, Nishizawa T, Takagi K et al. Antitumor mechanism of intradermal administration of lipopolysaccharide. Anticancer Res 1997; 17:1961-1964. (Pubitemid 27320934)
12. Inagawa H, Nishizawa T, Noguchi K et al. Anti-tumor effect of lipopolysaccharide by intradermal administration as a novel drug delivery system. Anticancer Res 1997; 17:2153-2158. (Pubitemid 27320961)
13. Dighe AS, Richards E, Old LJ et al, Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immun ity 1994; 1:447-456.
14. MacPherson GG, North RJ. Endotoxin-mediated necrosis and regression of established tumours in the mouse. A correlative study of quant itative changes in blood Rowand ultrastructu ral morphology. Cancer Immunol Imrnunother 1986; 21:209-216. (Pubitemid 16117961)
15. VukanovicJ, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis and macrophage infiltration within rat prostatic cancers. Cancer Res 1995; 55:1499-1504.
16. Blondiau C, Lagadec P, Lejeune P et al. Correlation between the capacity to activate macrophages in vitro and the antitumor activity in vivo of lipopol ysaccharides from different bacterial species. Immunobiol 1994; 190:243-254. (Pubitemid 24145642)
17. Jibu T, Koike Sando K et al. Antirnetasratic activity of lipopolysaccharide against a NK-resistant murine fibrosarcoma. Clin Exp Metastasis 1993; 11:306-312. (Pubitemid 23195954)
18. HarmeyJH, Bucana CD, Lu W et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumo r cell invasion. Int J Cancer 2002; 101:415-422.
19. Sato K, Yoo YC, Matsuzawa K et al. Tolerance to the anti-metastatic effect of lipopolysaccharide against liver metastasis in mice. Int J Cancer 1996; 66:98-103. (Pubitemid 26122324)
20. Ribi E, Amano K, CantrellJ et al. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol Immunother 1982; 12:91-96. (Pubitemid 12192020)
21. Qureshi N, Takayama K, Ribi E. Purification and structural determ ination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem 1982; 257:11808-11815. (Pubitemid 13218648)
22. Ukei S, Iida J, Shiba T et al. Adjuvant and antitumour activities of synthetic lipid A analogues. Vaccine 1986; 4:21-24. (Pubitemid 16129409)
23. Shimizu T, Sugiyama K, Iwamoto Y et al. Biological activities of chemically synthesized N accrylared serine-linked lipid A analog in mice. Int J Immunopharmacol 1994; 16:659-665. (Pubitemid 24238690)
24. Shimizu T, Iida K, Iwamoto Y et al. Biological activities and antirumor effects of synthetic lipid A analog linked N acerylated serine. Inr J Immunopharmacol 1995; 17:425-431.
25. Shimizu T, Iwamoto Y, Yanagihara Y et al. Comparison of the biological activity of synthetic N-acylared asparagine or serine linked monosaccharide lipid A analogs. Immunobiology 1996; 196:321-331. (Pubitemid 27075949)
26. Jeannin J-F, Onier N, Lagadec P et al. Antitumor effect of synthetic derivatives of lipid A in an experimental model of colon cancer in the rat. Gastroenterology 1991; 101:726-733.
27. Nakatsuka M, Kumazawa Y, Ikeda S et al. Antitumor and antimicrobial activities of lipid A-subunit analogue GLA-27. J Clin Lab Immunol1988; 26:43-47.
28. SarakeK, YokomatsuH, Hiura A. Effects of a new synthetic lipid A on endogenous tumor necrosis factor production and antitumor activity against human pancreatic cancer cells. Pancreas 1996; 12:260-266. (Pubitemid 26092763)
29. Onie r N, Lejeune P, Martin M et al, Involvement of T-Iymphocytes in curative effect of a new irnmunornodulator OM-163 on rat colon cancer metastases. Eur J Cancer 1993; 29A:2003-2009. (Pubitemid 23324362)
30. Nakatsuka M, Kumazawa Y, HommaJY et al. Inhibition in mice of experimental metastasis of B16 melanoma by the synthetic lipid A-subunit analogue GL-60. Inr J Immunopharmacol1991; 13:11-19.
31. Saiki I,Sato K, Yoo YC. Inhibition of rumor-induced angiogenesis by the administration of recombinant interferon-gamma followed by a synthetic lipid-A subunit analogue (GLA-60). Int J Cancer 1992; 51:641-645.
32. Fung PY, Madej M, Koganty RR et al. Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumor-associated glycoconjugate. Cancer Res 1990; 50:4308-4314. (Pubitemid 20225670)
33. Ogawa T, Nakazawa M, Masui K. Immunopharmacological activities of the nontoxic monophosphoryl lipid A of Porphyromonas gingivalis. Vaccine 1996; 14:70-76. (Pubitemid 26043133)
34. Samuel J. Budzynski WA, Reddish MA et al. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Ine J Cancer 1998; 75:295-302. (Pubitemid 28100073)
35. Kirman I, Asi Z. CarterJ et al. Combined whole tumor cell and monophosphoryl lipid A vaccine improved by encapsulation in murine colorectal cancer. Surg Endosc 2002; 16:654-658. (Pubitemid 34263431)
36. Kumazawa E, Tohgo A, Soga T et al. Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic rumor models. Cancer Immunol Immunother 1992; 35:307-314.
37. Saro K, Saiki I, Yoo YC et al. DT-5461, a new synthetic lipid A analogue, inh ibits lung and liver metastasis of rumor in mice. Jpn J Cancer Res 1992; 83:1081-1087.
38. limbo T, Akimoto T, Tohgo A. Effect of combined admin istration of a synthetic low-toxicity lipid A derivative. DT-5461a and indomethacin in various experimental rumor models of colon 26 carcinoma in mice. Cancer Immunol Immunother 1995; 40:10-16.
39. Sato K, Yoo YC, Matsuzawa K et al, Tolerance to the anti-metastatic effect of lipopolysaccharide against liver metastasis in mice. Int J cancer 1996; 66:98-103. (Pubitemid 26122324)
40. Akahane K, Sorneya K, Tsutomi Y et al. Antitumor synthetic lipid A analog DT-5461 upregulares cytokine expression in a murine macrophage cell line through LPS pathway. Cell Immunol 1994;155: 42-55.
41. Akirnoto T, Kumazawa E, Jimbo T et al, DT-5461a, an antitumor synthetic lipid a analog, causes selective blood flow reduct ion in rumor tissue. Anticancer Res 1995; 15:105-107.
42. Kumazawa E. Akimoro T, Kita Y et al. Intratumoral production of tumor necrosis factor augmented by endogenous interferons results in potent anritumor effects of DT-5461. a synthetic lipid A analog. J Irnrnunother Emphasis Tumor Immunol 1995; 17:141-150.
43. Sato K, Yoo YC, Mochizuki M et al. Inhibition of rumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461. Jpn J Cancer Res 1995; 86:374-382.
44. Jimbo T, Akimoto T. Tohgo A. Systemic administration of a synthetic lipid A derivative, DT-5461a, reduces rumor blood flow through endogenous TNF production in hepatic cancer model of VX2 carcinoma in rabbits. Anticancer Res 1996; 16:359-364. (Pubitemid 26129064)
45. Kobayashi M, NagayasuH, HamadaJ et al. ONO-4007, a new synthetic lipid A derivative, induces differentiation of rat myelomonocytic leukemia cells in vitro and in vivo. Exp Hematol 1994; 22:454-459. (Pubitemid 24150365)
46. Yang D, Sacoh M, Ueda H et al. Activation of rumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 1994; 38:287-293. (Pubitemid 24128005)
47. Sacoh M, Tsurumaki K, Kagehara H et al. Induction of intrarumoral rumor necrosis factor by a synthet ic lipid A analog (ONO-4007) with less tolerance in repeated administration and its implication in potent antirumor effects with low toxicity. Cancer Immunol Immunorher 2002; 50:653-662. (Pubitemid 34146570)
48. Inagawa H. Nishizawa T. Honda T et al, Mechanisms by which chemotherapeutic agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shili of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 1998; 18:3957-3964. (Pubitemid 28561087)
49. Takiguchi K, Nakamoto T, Inagawa H et al. Profile of cytokines produced in rumor tissue alier administration of cyclophosphamide in a combination therapy with rumor necrosis factor. Anticancer Res 2004; 24:1823-1828. (Pubitemid 38954716)
50. Morita S, Yamamoto M, Kamigaki T et al. Synthetic lipid A produces antitumor effect in a hamster pancreatic carcinoma model through production of tumor necrosis factor from activated macrophages. Kobe J Med Sci 1996; 42:219-231. (Pubitemid 27064719)
51. Mizushima Y, Sassa K, Fujishita T et al. Therapeutic effect of a new synthetic lipid A analog (ONO-4007) on a tumor implanted at diffetent sites in rats. J Imrnunother 1999; 22:401-406. (Pubitemid 29488757)
52. Kurarnitsu Y, Nishibe M, Ohiro Y et al. A new synthetic lipid A analog, ONO-4007, stimulates the production of tumor necrosis factor-alpha in tumor tissues, resulting in the rejection of transplanted rat hepatoma cells. Anticancer Drugs 1997; 8:500-508. (Pubitemid 27310920)
53. Kurarnirsu Y, Matsushita K, Ohiro Y et al. Therapeutic effect of a new synthetic lipid A analog, ONO-4007, on rat hepatoma KDH-8 depend on tumor necrosis facror-senslnvlry of the tumor cells. Anti-cancer Drugs 1997; 8:898-901. (Pubitemid 27487805)
54. Matsumoto N, Oida H, Aze Y et al. Intrarumoral tumor necrosis factor induction and tumor growth suppression by ONO-4007, a low-toxicity lipid A analog. Anticancer Res 1998; 18:4283-4289. (Pubitemid 29043646)
55. Matsushita K, Kobayashi M, Totsuka Y et al. ONO-4007 induces specific anti-tumor immunity mediated by tumor necrosis factor-alpha. Ant icancer Drugs 1998; 9:273-282. (Pubitemid 28186525)
56. Matsushita K, Kuramitsu Y, Ohiro Y et al. ONO-4007, a synthetic lipid A analog, induces Thl -rype immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages. Int J Oncol 2003; 32:489-493.
57. Brandenburg K, Lindner B, Schromm A et al. Physicochemical characteristics of rriacyl lipid A partial structure OM-174 in relation to biological activity. Eur J Biochem 2000; 267:3370-3377. (Pubitemid 30341167)
58. Onier N, Hilpert S, Arnould L et al. Cure of colon cancer metastasis in rats with the new lipid A OM 174. Apoptos is of tumor cells and immunization of rats. Clin Exp Merastas 1999; 17:299-306. (Pubitemid 29477575)
59. Onier N, Hilpert S, Reveneau S et al. Expression ofinducible nitric oxide synthase in tumors in relation with their regression induced by lipid A in rats. Inr J Cancer 1999; 81:755-760. (Pubitemid 29214386)
60. Lejeune P, Lagadec P, Onier N et al. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994; 152:5077-5083. (Pubitemid 24139103)
61. Reisser D, Pance A, Jeannin JE Mechanisms of the antitumoral effect of lipid A. Bioessays 2002; 24:284-289. (Pubitemid 34248695)
62. Lagadec P, Raynal S, Lieubeau B et al. Evidence for control of nitric oxide synthesis by intracellular transforming growth factor-beta1 in rumor cells. Implications for tumor development. Am J Pathol 1999; 154:1867-1876. (Pubitemid 29262870)
63. Lagadec P, Reveneau S, Lejeune P et al. Immunomodulator OM 163-induced reversal of tumor-mediated immunosuppression and downregulation of TGF -beta 1 in vivo. J Pharmacol Exp Ther 1996; 278:926-933. (Pubitemid 27167064)
64. Larmonier CB, Arnould L, Larmonier N et al. Kinetics of tumor cell apoptosis and immune cell activation during the regression of tumors induced by lipid A in a rat model of colon cancer. Inr J Mol Med 2004; 13:355-61.
65. D'Agostini C, Pica F, Febbraro G et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Inr Immununopharmacol 2005; 5:1505-1212.